JP2024523730A - 天然のライアビリティを含まないcdrを使用した抗体親和性成熟 - Google Patents

天然のライアビリティを含まないcdrを使用した抗体親和性成熟 Download PDF

Info

Publication number
JP2024523730A
JP2024523730A JP2024501196A JP2024501196A JP2024523730A JP 2024523730 A JP2024523730 A JP 2024523730A JP 2024501196 A JP2024501196 A JP 2024501196A JP 2024501196 A JP2024501196 A JP 2024501196A JP 2024523730 A JP2024523730 A JP 2024523730A
Authority
JP
Japan
Prior art keywords
antibody
cdr sequences
sequence
cdr3
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523730A5 (https=
Inventor
レイモン モートン ブラッドバリー アンドリュー
ディアンジェロ サラ
テイシェイラ アンドレ
Original Assignee
ルールズ-ベースド メディシン インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルールズ-ベースド メディシン インコーポレイティド filed Critical ルールズ-ベースド メディシン インコーポレイティド
Publication of JP2024523730A publication Critical patent/JP2024523730A/ja
Publication of JP2024523730A5 publication Critical patent/JP2024523730A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00Methods of creating libraries, e.g. combinatorial synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
JP2024501196A 2021-07-07 2022-07-07 天然のライアビリティを含まないcdrを使用した抗体親和性成熟 Pending JP2024523730A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218919P 2021-07-07 2021-07-07
US63/218,919 2021-07-07
PCT/US2022/036422 WO2023283383A1 (en) 2021-07-07 2022-07-07 Antibody affinity maturation using natural liability-free cdrs

Publications (2)

Publication Number Publication Date
JP2024523730A true JP2024523730A (ja) 2024-06-28
JP2024523730A5 JP2024523730A5 (https=) 2025-07-14

Family

ID=84801095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501196A Pending JP2024523730A (ja) 2021-07-07 2022-07-07 天然のライアビリティを含まないcdrを使用した抗体親和性成熟

Country Status (6)

Country Link
US (2) US20230167165A1 (https=)
EP (1) EP4366773A4 (https=)
JP (1) JP2024523730A (https=)
KR (1) KR20240056488A (https=)
CN (1) CN118103065A (https=)
WO (1) WO2023283383A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3246434A1 (en) * 2015-01-13 2017-11-22 Ewha University-Industry Collaboration Foundation Method for preparing novel antibody library and library prepared thereby
EP3728705A4 (en) * 2017-12-18 2022-01-19 Charles River Laboratories, Inc. RADICALLY DIVERSE HUMAN ANTIBODY LIBRARY
EP3833685A4 (en) * 2018-07-08 2022-08-17 Specifica Inc. ANTIBODY LIBRARIES WITH FEATURES FOR MAXIMIZED ANTIBODY DEVELOPMENT

Also Published As

Publication number Publication date
US20230167165A1 (en) 2023-06-01
EP4366773A1 (en) 2024-05-15
WO2023283383A1 (en) 2023-01-12
CN118103065A (zh) 2024-05-28
EP4366773A4 (en) 2025-11-05
US20240384438A1 (en) 2024-11-21
KR20240056488A (ko) 2024-04-30

Similar Documents

Publication Publication Date Title
Shi et al. De novo selection of high-affinity antibodies from synthetic fab libraries displayed on phage as pIX fusion proteins
Wark et al. Latest technologies for the enhancement of antibody affinity
JP5791496B2 (ja) 推定成熟cdrのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
US20240240360A1 (en) Antibody libraries with maximized antibody developability characteristics
JP2014077004A (ja) 多様な合成ペプチドおよびポリペプチドライブラリーの設計および構築
Teixeira et al. Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs
US20250020659A1 (en) Single domain antibody libraries with maximized antibody developability characteristics
US20240384438A1 (en) Antibody affinity maturation using natural liability-free cdrs
CN112424221B (zh) 抗体文库和使用抗体文库的抗体筛选方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250704